Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : IPHA save search
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.425 1.8K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph6501 first study
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
Published: 2023-04-03 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
IPHA | $2.425 1.8K
|
Health Technology
|
| O: 14.39%
H: 3.99%
C: -3.37%
pharma disease license research program
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | News | $128.15 2.31% 2.6M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $47.72 1.21% 1.1M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.425 1.8K
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | News | $70.93 1.14% 3.8M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
Gainers vs Losers
| 86% | 14% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.